NASDAQ$DH
Definitive Healthcare Corp · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Revenue exceeded guidance, and a $100 million repurchase authorization was announced.
Definitive Healthcare reported a revenue of $62.7 million, a decrease of 4% compared to Q3 2023. The company's financial performance exceeded the high end of its guidance on revenue, adjusted net income, and adjusted EBITDA. A stock repurchase program of up to $100 million was authorized.
- Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023.
- Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, down 24% compared to $(248.7) million in Q3 2023.
- Adjusted Net Income was $15.4 million, compared to $14.6 million in Q3 2023.
- Adjusted EBITDA was $20.6 million, down 5% from Q3 2023.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$62.7M
Forward guidance
The Company is issuing the following financial guidance. Revenue is expected to be in the range of $60.0 – $61.0 million. Adjusted Operating Income is expected to be in the range of $14.0 – $15.0 million. Adjusted EBITDA is expected to be in the range of $16.0 – $17.0 million, and 26 – 28 % adjusted EBITDA margin. Adjusted Net Income is expected to be $10.5 – $11.5 million. Adjusted Net Income Per Diluted Share is expected to be approximately $0.07 per share on approximately 154.4 million weighted-average shares outstanding.
Tailwinds
- Revenue is expected to be in the range of $60.0 – $61.0 million.
- Adjusted Operating Income is expected to be in the range of $14.0 – $15.0 million.
- Adjusted EBITDA is expected to be in the range of $16.0 – $17.0 million
- Adjusted EBITDA is expected to be 26 – 28 % adjusted EBITDA margin.
- Adjusted Net Income is expected to be $10.5 – $11.5 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro